Karyopharm Therapeutics Inc (KPTI) Stock Analysis

Karyopharm Therapeutics Inc (KPTI) is a publicly traded company in the HEALTHCARE sector. It trades at $9.23, carries a market capitalization of $222.55M. This page summarizes the public market data, fundamentals, and frequently asked questions for KPTI, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Karyopharm Therapeutics Inc currently has a Bullish sentiment score of 0.20.

About Karyopharm Therapeutics Inc

Karyopharm Therapeutics Inc. is a biopharmaceutical innovator headquartered in Newton, Massachusetts, specializing in the development of therapies that target nuclear export and key oncological pathways. Leveraging its proprietary SINE™ (Selective Inhibitor of Nuclear Export) technology platform, the company aims to address significant unmet medical needs in cancer care. Karyopharm's lead product, Xpovio (selinexor), has received multiple regulatory approvals, underscoring its commitment to i...

GNG Research Analysis

GNG Research scores Karyopharm Therapeutics Inc (KPTI) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for KPTI.

Frequently Asked Questions

Does KPTI pay dividends?

Karyopharm Therapeutics Inc (KPTI) does not currently pay a regular dividend.

What is KPTI's market cap?

Karyopharm Therapeutics Inc (KPTI) has a market capitalization of $222.55M with a current stock price of $9.23.